KLRS Q3 2022 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$180M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$199,000

Operating Income

-$43M

Net Income

-$42M

EPS (Diluted)

$-11.39

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$294M

Total Liabilities

$40M

Stockholders' Equity

$253M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$199,000	-$44,000	-352.3%
Operating Income	-$43M	-$46M	+5.6%
Net Income	-$42M	-$46M	+7.6%